Researcher
Serge Van Calenbergh
- Keywords:medicinal chemistry, nucleoside analogues, drug discovery, infectious diseases, glycosphingolipids
- Disciplines:Organic chemical synthesis, Bio-organic chemistry, Characterisation of biologically active (macro)molecules, Medicinal and biomolecular chemistry not elsewhere classified, Biomolecular modelling and design, Medicinal chemistry, Drug discovery and development not elsewhere classified
Affiliations
- Faculty Education Services Pharmaceutical Sciences (Administrative office)
Responsible
From1 Oct 2014 → 30 Sep 2022 - Faculty Education Services Pharmaceutical Sciences (Administrative office)
Member
From1 Oct 2014 → 30 Sep 2022 - Dean's Office of the Faculty of Pharmaceutical Sciences (Administrative office)
Member
From1 Sep 1997 → 31 Dec 1997 - Department of Pharmaceutics (Department)
Member
From1 Jan 1993 → Today
Projects
1 - 10 of 15
- Design and synthesis of inhibitors of the MEP pathwayFrom1 Jan 2024 → TodayFunding: BOF - doctoral mandates
- Uncaging the potential of photopharmacology for the treatment of epilepsyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Evaluation of a new treatment against "blackhead" disease in turkeys (POULTRY 2)From16 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Cofunding core facility - NMR Expertise CentreFrom1 Oct 2023 → TodayFunding: BOF - research organisations
- Identification of optimized Aurora Kinase A PROTACs with suitable PK properties for in vivo proof-of-concept studies (OPTIMAPK).From15 Jul 2023 → TodayFunding: IOF - technology concept exploration
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Targeting the degradation of proteins involved in neuroblastoma with bivalent ligands.From1 Nov 2020 → TodayFunding: FWO Strategic Basic Research Grant
- Novel treatment for blackhead disease in turkeysFrom3 Aug 2020 → 30 Jun 2022Funding: IOF - technology concept exploration
- Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti-infectivesFrom1 Apr 2020 → TodayFunding: H2020-EU.1.3.- EXCELLEN SCIENCE - Marie Skłodowska-Curie actions
- Identification of adaptive mechanisms leading to reduced antibiotic susceptibility in bacterial biofilms using experimental evolution and machine learning approachesFrom1 Jan 2020 → TodayFunding: BOF - projects
Publications
21 - 30 of 38
- Cytotoxic activity of Laserpitium latifolium L. extract and its daucane and phenylpropanoid constituents(2013)
Authors: Visnja Popovic, Arne Heyerick, Silvana Petrovic, Serge Van Calenbergh, Izet Karalic, Marjan Niketic, Dieter Deforce
Pages: 245 - 249 - The bovine CD1D gene has an unusual gene structure and is expressed but cannot present U+03B1-galactosylceramide with a C26 fatty acid(2013)
Authors: Kim Anh Nguyen Thi, Ad P Koets, Martin Vordermeier, Peter J Jervis, Liam R Cox, Simon P Graham, Wiebren J Santema, D Branch Moody, Serge Van Calenbergh, Dirk M Zajonc, et al.
Pages: 91 - 98 - Structural basis for the recognition of C20:2-U+03B1GalCer by the invariant natural killer T-cell receptor-like antibody L363(2012)
Authors: Esther Dawen Yu, Enrico Girardi, Jing Wang, Thien-Thi Mac Mac, Karl OA Yu, Serge Van Calenbergh, Steven A Porcelli, Dirk M Zajonc
Pages: 1269 - 1278 - Drug design and identification of potent leads against Mycobacterium tuberculosis thymidine monophosphate kinase(2012)
Authors: Serge Van Calenbergh, S Pocet, H Munier-Lehmann
Pages: 694 - 705 - Galactose modified iNKT cell agonists stabilised by a novel structural modification of CD1D lead to marked TH1 polarisation in vivo(2011)Volume: 70
Authors: Sandrine Aspeslagh, YaLi Li, Esther Dawen Yu, Nora Pauwels, Matthias Trappeniers, Enrico Girardi, Tine Decruy, Katrien Van Beneden, Koen Venken, Michael Drennan, et al.
Pages: A53 - A53 - 6''-Modified alpha-GalCer analogs capable of establishing an extra interaction with Cd1d leading to a polarized Th1 response and superior tumor protection(2011)Volume: 241
Authors: Serge Van Calenbergh, Nora Pauwels, Sandrine Aspeslagh, YaLi Li, Matthias Trappeniers, Dirk Zajonc, Dirk Elewaut
Number of pages: 1 - Optimizing the iNKT cell dependent antitumor effect using an altered glycolipid(2010)Volume: 135
Authors: Sandrine Aspeslagh, Yali Li, Tine Decruy, Katrien Van Beneden, Koen Venken, Matthias Trappeniers, Serge Van Calenbergh, Dirk Zajonc, Dirk Elewaut
Pages: S40 - S40 - Transport and delivery of antimicrobial agents in Burkholderia biofilms(2010)Volume: 148
Authors: Katrien Forier, Anne-Sophie Messiaen, Tom Coenye, Hans Nelis, Shari Celen, Serge Van Calenbergh, Stefaan De Smedt, Jo Demeester, Kevin Braeckmans
Pages: E35 - E36 - Optimizing the iNKT cell dependent antitumor effect using an altered glycolipid(2010)Volume: 135
Authors: Sandrine Aspeslagh, Yali Li, Tine Decruy, Katrien Van Beneden, Michael Drennan, Koen Venken, Matthias Trappeniers, Serge Van Calenbergh, Dirk Zajonc, Dirk Elewaut
Pages: S13 - S14 - Suppression of human natural killer T cell function by CD4(+)CD25(+)FOXP3(+) regulatory T cells(2010)Volume: 28
Authors: Koen Venken, Tine Decruy, Kim Deswarte, Sandrine Aspeslagh, Serge Van Calenbergh, Bart Lambrecht, Dirk Elewaut
Pages: 614 - 614
Patents
1 - 10 of 10
- Nucleoside analogues for the treatment of parasitic infections (Inventor)
- Sphingamide Compounds and Methods for Binding iNKT Cells (Inventor)
- Nucleoside analogues for the treatment of parasitic infections (Inventor)
- Sphingamide Compounds and Methods for Binding iNKT Cells (Inventor)
- GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS (Inventor)
- Nucleoside analogues for the treatment of parasitic infections (Inventor)
- HAMAMELITANNIN ANALOGUES AND USES THEREOF (Inventor)
- HAMAMELITANNIN ANALOGUES AND USES THEREOF (Inventor)
- NOVEL HAMAMELITANNIN ANALOGUES AND USES THEREOF (Inventor)
- GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS (Inventor)